top of page
Our Pipeline
Akamis Bio Header Image

Our Pipeline

A growing pipeline of T-SIGn® therapeutics aiming to enable a patient’s immune system to recognize, attack, and clear solid tumors.

Akamis Bio has a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.

 

With more than 200 patients treated across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.

Stage

Product

Transgene

Payload

Principal

Mechanism

NG-350A

Two transgenes:

producing a secreted CD40 agonist monoclonal antibody

CD40 agonism

Phase 1

Phase 2

Phase 3

Research

IND

Enabling

Worldwide Rights

Akamis Therapeutics Virus V2.png
Akamis Bio 2 Transgene

NG-7XX

Three transgenes:

producing IL-12, IL-15 and a chemokine

T-cell and

NK-cell 

activation

Akamis Therapeutics Virus V2.png
Akamis Bio Three transgenes

Product Concept: Tumor-specific delivery of potent immune cell recruitment & activating agents avoiding systemic toxicity

Product Concept: Tumor-specific delivery of CAR-T targets to enhance the efficacy and/or improve the safety profile of the cell therapy

Undisclosed

Various:

Transgene payload packages including natural and synthetic tumor antigens

CAR T-cell targeting & activation

Undisclosed

Akamis Therapeutics Virus V2.png
Akamis Bio 4 Transgene.png
bottom of page